
TORONTO, Oct. 6 /CNW/ - Patheon Inc. (TSX: PTI) today announced that its subsidiary, CEPH International Corporation, has filed its response letter to the US Food & Drug Administration (FDA) in connection with the Warning Letter it received on September 16, 2005. Results for the fourth quarter ending October 31, 2005 are expected to be negatively impacted by approximately 3 cents per share as a result of the decision, taken by CEPH after receipt of the Warning Letter, to suspend production of the Omnicef powder for oral suspension product and the additional costs incurred to address the matter. CEPH, with the assistance of experts from Patheon, its client and external consultants worked diligently to analyze the issues raised by the FDA and to develop an enhanced process improvement program to address the FDA's concerns. CEPH is currently implementing process improvements consistent with the program outlined in the response letter to the FDA. Although Patheon currently anticipates that it will re-commence normal production of the Omnicef powder for suspension product in the first quarter of its 2006 fiscal year, the actual timing will be dependent on the FDA's response to CEPH's response letter. Patheon (TSX:PTI; www.patheon.com) is a leading global provider of drug development and manufacturing services to the international pharmaceutical industry. With the addition of its wholly owned subsidiary MOVA Pharmaceutical Corporation, acquired in December 2004, Patheon operates a network of 14 facilities in the United States, Canada and Europe, employing more than 5,900 people and serving a client base of 180 pharmaceutical and biotechnology companies. This news release contains forward-looking statements with respect to Patheon, including its business operations and strategy and financial performance and condition. Although management believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from expectations include, but are not limited to, currency fluctuations, the level of outsourcing services required by the pharmaceutical companies (and in particular our clients), the impact of changes in pharmaceutical development and manufacturing regulations and general economic and market factors (including inflation and changes in laws) and other factors discussed in materials filed with applicable securities regulatory authorities from time to time. %SEDAR: 00001700E